诺托金森化物R1可以抑制FGF1和VEGFA之间的相互作用,以减缓Podocyte亡
ChangYan Li1, HuaChen Zhong2, JingYuan Ma1
1Department of Nephrology, the First Affiliated Hospital of Kunming Medical University, No.295, Xichang Road, Kunming, Yunnan Province, 650032, China.
BMC endocrine disorders
|July 6, 2023
概括
诺托金化物R1 (NGR1) 抑制了血管内皮生长因子A (VEGFA) 和纤维细胞生长因子1 (FGF1) 之间的相互作用. 这种作用减缓了糖尿病脏病患者的 podocyte 亡,提供了一个潜在的治疗策略.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 糖尿病病 (DN) 涉及高葡萄糖环境中的微血管病,血管损伤通常与VEGFA相关.
- 传统的抗炎药物Notoginsenoside R1 (NGR1) 显示出血管活性.
- 鉴定在DN中保护血管炎症的药物至关重要.
研究的目的:
- 调查NGR1对糖尿病病中血管损伤的保护作用.
- 阐明NGR1作用背后的分子机制,重点关注VEGFA和FGF1相互作用.
主要方法:
- 使用Limma方法进行淋巴细胞转录组分析.
- 针对NGR1药物点的瑞士目标预测 (斯皮尔曼算法).
- 分子对接和共免疫沉 (COIP) 验证蛋白质相互作用.
主要成果:
- NGR1通过键可能与VEGFA和FGF1结合.
- NGR1 阻碍了 VEGFA 和 FGF1.1 之间的相互作用.
- 在高葡萄糖条件下,NGR1抑制了VEGFA和FGF1的表达,减缓了podocyte的亡.
结论:
- NGR1 抑制了 FGF1-VEGFA 相互作用,从而减缓了 DN 中的 podocyte 亡.
- 通过减轻血管炎症和细胞死亡,NGR1显示出作为糖尿病病治疗剂的潜力.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
TGF - β Signaling Pathway
7.5K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.5K


